|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
multiple interactions increases activity |
EXP |
chromium protoporphyrin IX promotes the reaction [Gossypol results in increased activity of ALAS1 protein] |
CTD |
PMID:15027808 |
|
NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
[Gossypol co-treated with Methyltestosterone co-treated with Ethinyl Estradiol] results in increased expression of BAX mRNA [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of BAX mRNA] |
CTD |
PMID:15451339 PMID:34699866 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Gossypol results in increased expression of BBC3 protein |
CTD |
PMID:18840529 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of BCL2 mRNA]; [gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of BCL2 mRNA; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of BCL2 mRNA] |
CTD |
PMID:34699866 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
Gossypol analog binds to and affects the activity of BCL2L1 protein Gossypol results in decreased expression of BCL2L1 protein |
CTD |
PMID:16020667 PMID:18840529 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
Gossypol results in increased expression of BCL2L11 protein |
CTD |
PMID:18840529 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein] |
CTD |
PMID:35872041 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO EXP |
[zoledronic acid co-treated with Gossypol] results in increased activity of CASP3 protein Gossypol results in increased cleavage of CASP3 protein [Gossypol co-treated with Methyltestosterone co-treated with Ethinyl Estradiol] results in increased expression of CASP3 mRNA Gossypol results in increased activity of CASP3 protein |
CTD |
PMID:15451339 PMID:18840529 PMID:19825521 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
[zoledronic acid co-treated with Gossypol] results in increased activity of CASP7 protein Gossypol results in increased activity of CASP7 protein |
CTD |
PMID:19825521 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Gossypol results in increased cleavage of CASP9 protein [gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of CASP9 protein]; [gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of CASP9 protein; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of CASP9 protein] [Gossypol co-treated with Methyltestosterone co-treated with Ethinyl Estradiol] results in increased expression of CASP9 mRNA |
CTD |
PMID:15451339 PMID:18840529 PMID:34699866 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased activity of CAT protein]; [gossypol acetic acid results in increased abundance of Gossypol] which results in increased activity of CAT protein; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased activity of CAT protein] |
CTD |
PMID:34699866 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO |
Gossypol results in decreased expression of CCL2 mRNA zoledronic acid promotes the reaction [Gossypol results in decreased expression of CCL2 mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
EXP |
Gossypol results in decreased expression of CDH2 protein |
CTD |
PMID:15082077 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[zoledronic acid co-treated with Gossypol] results in decreased expression of CXCL1 mRNA |
CTD |
PMID:19825521 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[zoledronic acid co-treated with Gossypol] results in decreased expression of CXCL1 mRNA |
CTD |
PMID:19825521 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
[Gossypol results in decreased phosphorylation of EIF4EBP1 protein] inhibits the reaction [Epirubicin results in increased expression of BIRC5 protein]; Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:35872041 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ephb4 |
EPH receptor B4 |
multiple interactions |
ISO |
[zoledronic acid co-treated with Gossypol] results in decreased expression of EPHB4 mRNA |
CTD |
PMID:19825521 |
|
NCBI chr12:19,326,411...19,351,667
Ensembl chr12:19,326,427...19,351,314
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
[Gossypol co-treated with Methyltestosterone co-treated with Ethinyl Estradiol] results in increased expression of FAS mRNA |
CTD |
PMID:15451339 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression multiple interactions |
ISO |
Gossypol results in decreased expression of FGF2 mRNA zoledronic acid promotes the reaction [Gossypol results in decreased expression of FGF2 mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression multiple interactions |
ISO |
Gossypol results in decreased expression of FGFR3 mRNA zoledronic acid promotes the reaction [Gossypol results in decreased expression of FGFR3 mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
multiple interactions |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of FGFR4 mRNA]; [gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of FGFR4 mRNA; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of FGFR4 mRNA] |
CTD |
PMID:34699866 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
decreases expression |
EXP |
Gossypol results in decreased expression of GJA1 protein |
CTD |
PMID:15082077 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases activity |
EXP |
chromium protoporphyrin IX inhibits the reaction [Gossypol results in increased activity of HMOX1 protein] |
CTD |
PMID:15027808 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b8 |
hydroxysteroid (17-beta) dehydrogenase 8 |
multiple interactions |
ISO |
[Gossypol co-treated with NAD] binds to HSD17B8 protein |
CTD |
PMID:25526675 |
|
NCBI chr20:4,826,725...4,828,742
Ensembl chr20:4,822,026...4,828,742
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
decreases expression multiple interactions |
ISO |
Gossypol results in decreased expression of ID1 mRNA zoledronic acid promotes the reaction [Gossypol results in decreased expression of ID1 mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Lama5 |
laminin subunit alpha 5 |
multiple interactions |
ISO |
[zoledronic acid co-treated with Gossypol] results in decreased expression of LAMA5 mRNA |
CTD |
PMID:19825521 |
|
NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:35872041 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:35872041 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
Gossypol results in decreased expression of MCL1 protein |
CTD |
PMID:18840529 PMID:20587533 PMID:21750559 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdk |
midkine |
decreases expression multiple interactions |
ISO |
Gossypol results in decreased expression of MDK mRNA zoledronic acid promotes the reaction [Gossypol results in decreased expression of MDK mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr 3:77,901,156...77,903,997
Ensembl chr 3:77,901,158...77,903,130
|
|
G |
Otc |
ornithine transcarbamylase |
multiple interactions |
EXP |
Gossypol inhibits the reaction [PRL protein results in increased activity of OTC protein]; Gossypol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of OTC protein] |
CTD |
PMID:3097147 |
|
NCBI chr X:12,453,834...12,529,954
Ensembl chr X:12,453,834...12,566,918
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Gossypol co-treated with Epirubicin] results in increased cleavage of PARP1 protein |
CTD |
PMID:35872041 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions |
ISO |
[zoledronic acid co-treated with Gossypol] results in decreased expression of PDGFA mRNA |
CTD |
PMID:19825521 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Prl |
prolactin |
multiple interactions |
EXP |
Gossypol inhibits the reaction [PRL protein results in increased activity of OTC protein] |
CTD |
PMID:3097147 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
Gossypol inhibits the reaction [Epirubicin results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:35872041 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in increased expression of TRP53 protein]; [gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of TRP53 protein; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in increased expression of TRP53 protein] |
CTD |
PMID:34699866 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tymp |
thymidine phosphorylase |
multiple interactions |
ISO |
Gossypol inhibits the reaction [zoledronic acid results in increased expression of TYMP mRNA] |
CTD |
PMID:19825521 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[gossypol acetic acid results in increased abundance of Gossypol] promotes the reaction [ponatinib results in decreased expression of VEGFA protein]; [gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of VEGFA protein; ponatinib promotes the reaction [[gossypol acetic acid results in increased abundance of Gossypol] which results in decreased expression of VEGFA protein] |
CTD |
PMID:34699866 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|